Plaque Psoriasis - Pipeline Insight, 2024

This “Plaque Psoriasis - Pipeline Insight, 2024,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Plaque Psoriasis Understanding

Plaque Psoriasis: Overview

Psoriasis is recognized as the most prevalent immune-mediated inflammatory disease, involving skin and joints and associated with abnormalities of other systems. Plaque psoriasis is the commonest clinical type of psoriasis. Even though the condition is not life-threatening, it is difficult to treat and response rates vary widely. Plaque psoriasis typically presents with large oval-circular plaques over the scalp, trunk and extensor body surface. The plaques have an extensive amount of scaling due to the hyperproliferation of the epidermal cells. Most patients have acute flares and relapses of plaque psoriasis, which may sometimes become severe and progress into the pustular subtype. At least 15% of patients with plaque psoriasis will develop psoriatic arthritis. Plaque psoriasis is asymptomatic in many individuals but can cause considerable itching, especially when there is an involvement of the scalp. Some people complain of soreness or pain due to fissuring, particularly affecting the palms and soles. Plaque psoriasis is asymptomatic in many individuals but can cause considerable itching, especially when there is an involvement of the scalp. Some people complain of soreness or pain due to fissuring, particularly affecting the palms and soles.

Plaque Psoriasis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Plaque Psoriasis pipeline landscape is provided which includes the disease overview and Plaque Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Plaque Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Plaque Psoriasis.
• In the coming years, the Plaque Psoriasis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Plaque Psoriasis treatment market. Several potential therapies for Plaque Psoriasis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Plaque Psoriasis market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Plaque Psoriasis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Plaque Psoriasis Emerging Drugs Chapters

This segment of the Plaque Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Plaque Psoriasis Emerging Drugs

ARQ-151: Arcutis Biotherapeutics Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase-4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases the production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the systemic treatment of plaque psoriasis and the topical treatment of atopic dermatitis. Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopicdermatitis.

ABY-035: Affibody ABY-035 is a novel bispecific agent, potently targeting both subunits of IL-17A as well as albumin. ABY-035 has been specifically designed to utilize the strengths of Affibody’s technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serumalbumin.

AK101: Akeso Biopharma AK101 injection is a novel antibody drug developed independently by the Company under the National Major Innovative Drug Projects. It is intended to be used for the treatment of autoimmune diseases such as psoriasis, Crohn’s disease, ulcerative colitis and lupus. AK101 clinically treats autoimmune diseases by blocking the biological activities of cytokines IL-12 and IL-23. Johnson & Johnson’s Ustekinumab (trade name: Stelara) which has the same drug targets has been approved by the FDA for the treatment of psoriasis, Crohn’s disease, and ulcerative colitis, and yielded US$6.4 billion in sales in 2019. Currently, it is in Phase III stage of clinical trial evaluation to treat PlaquePsoriasis.

Plaque Psoriasis: Therapeutic Assessment

This segment of the report provides insights about the different Plaque Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Plaque Psoriasis

There are approx. 75+ key companies which are developing the therapies for Plaque Psoriasis. The companies which have their Plaque Psoriasis drug candidates in the most advanced stage, i.e. preregistration include, Arcutis Biotherapeutics.

Phases

This report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Plaque Psoriasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Plaque Psoriasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plaque Psoriasis drugs.

Plaque Psoriasis Report Insights

• Plaque Psoriasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Plaque Psoriasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Plaque Psoriasis drugs?
• How many Plaque Psoriasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Plaque Psoriasis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Plaque Psoriasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Plaque Psoriasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arcutis Biotherapeutics
• Affibody
• Akeso Biopharma
• Dong-A ST Co., Ltd.
• Del Arrivo,Inc.
• Bristol-Myers Squibb
• Bio-Thera Solutions
• Janssen Research & Development, LLC
• Meiji Pharma USA Inc.
• Aldeyra Therapeutics, Inc.
• Amgen
• Bioeq GmbH
• Can-Fite Biopharma
• Hangzhou Highlightll Pharmaceutical Co., Ltd
• Nimbus Therapeutics
• Sun Pharmaceutical Industries
• Jiangsu Hengrui Medicine
• Biocon
• Pfizer
• Ono Pharmaceutical
• GC Cell Corporation
• Suzhou Zelgen Biopharmaceuticals
• Aurigene Discovery Technologies Limited
• Celltrion
• Tianjin Hemay Pharmaceutical Co., Ltd
• Innovent Biologics (Suzhou) Co. Ltd.
• Sinocelltech
• Azora Therapeutics

Key Products

• ARQ-151
• ABY-035
• AK101
• DMB-3115
• DLX105-DMP
• Deucravacitinib
• BAT2306
• JNJ-77242113
• ME3183
• ADX-629
• ABP 654
• GLPG3667
• FYB202
• CF101
• TLL018
• NDI-034858
• SCD-044
• SHR-1314
• Bmab1200
• PF-07038124
• ONO-4685
• CT303
• Jaktinib
• AUR101
• CT-P43
• Hemay005
• IBI112
• SCT630
• AT193

This product will be delivered within 1-3 business days.